Medical Drugs News
-
Showcase
Empatica and BARDA Join Forces to Validate Wearable System That Detects COVID-19 Before Symptoms Appear
BOSTON, June 19, 2020 /PRNewswire/ -- Digital healthcare company Empatica announces a pioneering new partnership with the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), to validate an early warning system for COVID-19 and other respiratory ...
-
Showcase
ALung Announces Commercial Development of its Breakthrough Next Generation Artificial Lung
PITTSBURGH–(BUSINESS WIRE)– April 4, 2020 – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the recent initiation of commercial development of its next generation artificial lung, which expands the Company’s focus on highly efficient gas ...
-
Creative Enzymes Expands Its Service Offering with the Launch of Native Horseradish Peroxidase
Creative Enzymes, a professional enzyme provider located in New York, USA, is always hammering away at research and trials in order to provide customers with as many enzyme services and products as possible. Creative Enzymes recently announced the launch of Horseradish Peroxidase for research and industrial production. Horseradish peroxidase, abbreviated as HRP, is a single-chain polypeptide ...
-
Creative Enzymes Introduces DNA Modifying Enzymes for Molecular Biology Research
Creative Enzymes, an excellent supplier and manufacturer located in New York, is always hammering away at research and trials in order to provide customers with as many enzyme services and products as possible. DNA modifying enzymes play an important role in molecular biology research. With the aim of developing efficient enzyme tools to better support your research, Creative Enzymes is pleased ...
-
Xilis Participates in €325MM Oncode-PACT Consortium to Accelerate the Development of Cancer Drugs
Xilis, Inc., a pioneering company developing its MicroOrganoSphere™ (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that it is participating in the recently announced public-private Oncode-PACT. Led by the Netherlands-based Oncode Institute, the consortium will be supported by the National Growth Fund, an ...
By XILIS, Inc.
-
Xilis Presents Data at ESMO 2021 Demonstrating Capabilities of MicroOrganoSphere Technology for Cancer Drug Screening
Data suggests MOS platform recapitulates primary tumor tissue heterogeneity, including genomic and transcriptomic features, and microenvironment, comprising immune and stromal components MOS can be used in the evaluation of cancer drug response for chemotherapies and immunotherapies in the research setting Xilis, Inc., a pioneering company developing its MicroOrganoSphere (MOS) technology ...
By XILIS, Inc.
-
Maia connected care is born, the telemedicine solution developed by ab medica
20 years of experience for a platform already tested, effective, fully integrable with the hospital flow and in continuous evolution. Ab medica starts from the many years of monitoring, developing a Class IIA Medical Device, compliant with the GDPR regulation and easily integrated with public and private information systems. Maia connected care is a modular platform that allows ...
-
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress on June 25, 2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research, will present the results of Altimmune’s recently completed Phase 1, first-in-human clinical trial of pemvidutide in an oral presentation at the European Association for the Study of the Liver (EASL) International Liver ...
-
Esteve Launches INBRIJA in Germany
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Esteve Pharmaceuticals GmbH has launched INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) in Germany. INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor.(1) Under ...
-
Women’s Brain Project and Altoida Announce Results Highlighting Sex-Based Differences Using Predictive Digital Biomarker in Alzheimer’s Disease
The Women’s Brain Project, an international non-profit organization studying gender and sex determinants to brain and mental health and Altoida, a precision neurology company pioneering non-invasive brain health diagnostics using AI and augmented reality (AR), today announced results from a study showing sex-based differences using digital biomarker data collected from Altoida’s ...
-
MindChild Medical, Inc. Announces FDA Clearance for M110 Monitor
(BusinessWire, North Andover, Massachusetts), MindChild Medical, Inc. today announced that it has received clearance for its Pre-Marketing Notification (510(k)) from the US Food and Drug Administration (FDA) for its MERIDIAN™ M110 non-invasive fetal heart monitor. MindChild anticipates entering the US market with MERIDIAN now that it has received the FDA clearance. ...
-
What Are D-Glucosamines?
Glucosamine is a natural component of cartilage and is widely used as an over-the-counter nutritional supplement to reduce the pain and cartilage loss of osteoarthritis. Glucosamine is usually taken in combination with chondroitin, which is a glycosaminoglycan that also exists in cartilage.Glucosamine is an amino sugar and an important molecule in the biochemical pathway of glycosylated protein ...
-
CD Bioparticles Releases Prostaglandins to Support Drug Delivery Research
CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, now introduces a series of prostaglandins products to support drug delivery related research. These new products offer comprehensive choices for researchers, such as Prostaglandin F2a (11beta epimer), Prostaglandin A1, Prostaglandin F1ß, Prostaglandin E2, and Prostaglandin E1-d9. CD ...
-
Midatech Pharma Outlines Board Changes
R&D biotechnology company Midatech Pharma has revealed changes to its board, following its chairman announcing his intention to retire. Rolf Stahel will step down from the board on 20 June 2022 and it is expected that Stephen Parker will be appointed as non-executive chairman, following the AGM. Parker will join the Cardiff-based company, which works on improving the bio-delivery ...
By MediWales
-
Creative Diagnostics Launches Measles Virus Antigens for the Detection of Antibodies
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for bio-technology industry, recently announced the release of new measles virus antigens suitable for both IgM and IgG detection. These new products are intended for research use only and are not diagnostic use. Measles virus (MeV) is a negative-sense RNA virus with a non-segmented genome and lipid envelope ...
-
Creative Diagnostics Introduces CC50/IC50 Assay Services for Pharmaceutical Safety
As a consulting and experimental service provider specializing in virology and microbiology, Creative Diagnostics recently introduced CC50/IC50 Assay service with a high level of assay sensitivity and accuracy. The CC50 and IC50 will be plotted using a sigmoidal dose-response curve, and the selectivity index (SI) for each compound is estimated by dividing the CC50 with the IC50. Pharmaceutical ...
-
STEMart Launches Microbiology & Sterility Testing Services for Medical Devices
STEMart, a provider of integrated medical device CRO services dedicated to medical device and diagnostic clinical development, introduces comprehensive microbiology and sterility testing for sterile, non-pyrogenic products. STEMart has extensive expertise in microbiology as well as sterility testing and remains dedicated to a full-service experience that supports manufacturers in meeting ...
By STEMart
-
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
Plan ensures shareholders are protected and treated equitably Does not prevent the Zymeworks Board from engaging on future acquisition proposal that is in the best interests of all shareholders VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Jun. 10, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional ...
-
BOC Sciences Grandly Promotes: One-Stop CDMO Service Platform for Drug Development
BOC Sciences recently initiated an unprecedentedly comprehensive CDMO service platform to accelerate technology transfer of medicines from research to commercial scale. CDMO services are not new at BOC Sciences. Rather, as a reputed CDMO service provider, BOC Sciences has extensively contributed to the development and production of small molecules, oligonucleotides, peptides, various chemically ...
By BOC Sciences
-
BOC Sciences Grandly Promotes: One-Stop CDMO Service Platform for Drug Development
BOC Sciences recently initiated an unprecedentedly comprehensive CDMO service platform to accelerate technology transfer of medicines from research to commercial scale. CDMO services are not new at BOC Sciences. Rather, as a reputed CDMO service provider, BOC Sciences has extensively contributed to the development and production of small molecules, oligonucleotides, peptides, various chemically ...
By BOC Sciences
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you